There’s a common assumption that blood tests are the gold standard for diagnostics, but when it comes to mold, the picture is more nuanced. Despite measuring the body’s immune response, blood tests don’t directly measure toxins, complicating the process of navigating environmental mold exposure.
We connected with Dennis Hooper, Pathologist, expert in environmental medicine, and Founder of RealTime Labs, to hear how urine-based toxicology is advancing mold exposure testing.
Mold exposure remains a complex and often controversial area – what makes it particularly challenging to diagnose from a pathology and laboratory medicine perspective?
The main challenge is that traditional pathology focuses on identifying the fungus itself, rather than the toxins it produces. Clinicians typically rely on cultures or stained tissue samples to detect fungal structures, but these methods cannot identify mycotoxins.
Mycotoxins are small chemical compounds that drive disease but cannot be seen under a standard microscope. As a result, laboratories need to move beyond visual detection and use specialized tests to identify these toxins in the body.
To address this gap, we use sensitive ELISA-based assays that can detect multiple clinically relevant mycotoxins in patient urine.
What are the key limitations of current testing methodologies when attempting to link mold exposure to patient symptoms?
A key limitation is that symptoms of mycotoxin exposure – such as fatigue, headaches, and rashes – are non-specific and can resemble many other conditions, including autoimmune diseases.
From a laboratory perspective, the first step is to confirm the presence of mycotoxins in the body. However, linking these findings to a patient’s symptoms requires a detailed clinical and environmental history to identify potential mold exposure.
Demonstrating that toxin-producing fungi are present in the patient’s environment can help connect non-specific symptoms to mycotoxin exposure.
How does immune response testing contribute to our understanding of mold-related illness, and which markers are most clinically informative?
Immune response testing – such as IgG, IgM, and IgE antibody panels – can help indicate whether a patient has been exposed to a mold or antigen. IgM reflects a recent response, IgG suggests longer-term exposure, and IgE is associated with allergic reactions.
However, these markers only show that the immune system has encountered the antigen; they do not confirm the presence of active mycotoxins or ongoing toxicity. As a result, relying solely on antibody testing may lead to the assumption of active exposure when it may instead reflect past exposure or immune sensitization.
Why is it important to distinguish between immune response testing and toxicology testing in this context, and how can confusion between the two affect clinical decision-making?
Distinguishing between these tests is critical because immune response testing reflects past exposure, while toxicology testing identifies toxins currently present in the body. If the two are confused, clinicians may mistake a previous exposure for an active condition, potentially leading to inappropriate treatment. Urine-based toxicology testing can help identify active toxins and support more targeted management, reducing the risk of unnecessary or inappropriate interventions.
Urine-based mycotoxin testing is increasingly discussed – what role do you see it playing in the diagnostic pathway for patients with suspected mold exposure?
Urine-based mycotoxin testing can help identify toxins that the body is currently processing and excreting. Unlike blood antibody tests, which reflect past exposure, urine testing may provide additional information about potential ongoing exposure.
This approach can support clinical decision-making by offering measurable results alongside clinical evaluation and patient history. Urine testing is also non-invasive and provides standardized, quantitative data that can be easier to interpret.
In what situations might urine-based approaches offer more clinically useful insights than other testing modalities?
Urine-based testing may be most useful in patients with persistent, unexplained symptoms when clinicians need to assess possible active toxin exposure. In cases where patients have undergone multiple evaluations without a clear diagnosis, immune-based tests may provide limited or historical information.
In these situations, urine testing can offer additional insight into current exposure and help guide further clinical assessment. This approach may be particularly relevant when environmental sources, such as mold exposure, are suspected, including toxins like macrocyclic trichothecenes.
How can pathologists and laboratory professionals best support clinicians in navigating the diagnostic uncertainty surrounding environmental mold exposure?
Laboratory professionals play an important role in educating clinicians about the science behind mycotoxin testing. This may include webinars or clinical seminars that explain key concepts, such as the difference between foodborne exposure and environmental sources like macrocyclic trichothecenes.
By sharing validated data and peer-reviewed evidence, pathologists can help support informed use of these tests and improve confidence in their interpretation. Some laboratories also offer clinical support services to assist healthcare professionals in understanding and applying test results in practice.
Looking ahead, what advances or standardization efforts are needed to improve the accuracy and clinical utility of mold-related diagnostics?
The field would benefit from stronger adherence to established laboratory accreditation standards, such as CAP and CLIA, to ensure test quality and consistency. Expanding the clinical evidence base – particularly studies linking environmental exposures with measurable findings in patient samples – may also help clarify the role of mycotoxin testing in practice.
Further research into dose–response relationships, including variability in patient sensitivity, could improve how these cases are interpreted and managed. At the same time, it is important that laboratories remain grounded in rigorous scientific validation and avoid unsupported clinical claims. Continued publication of peer-reviewed research will be essential to distinguish validated diagnostic approaches from less established testing.
Ultimately, the goal is to provide reliable, standardized data that support clinicians in managing complex cases. A sustained focus on scientific rigor and transparency will help improve diagnostic clarity and patient care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
